Home » Stocks » CBPO

China Biologic Products Holdings, Inc. (CBPO)

Stock Price: $118.00 USD 0.15 (0.13%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
Market Cap 4.57B
Revenue (ttm) 514.40M
Net Income (ttm) 141.06M
Shares Out 38.79M
EPS (ttm) 3.57
PE Ratio 33.06
Forward PE 21.19
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $118.00
Previous Close $117.85
Change ($) 0.15
Change (%) 0.13%
Day's Open 117.86
Day's Range 117.53 - 118.40
Day's Volume 194,386
52-Week Range 97.91 - 120.01

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 3 months ago

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

BEIJING, Nov. 13, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical comp...

InvestorPlace - 4 months ago

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

Other stocks mentioned: GLPG, HRTX, ILMN, IONS, RGNX, LGND
Seeking Alpha - 6 months ago

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call Transcript

GuruFocus - 8 months ago

The following companies have grown their earnings per share over a five-year period.

Other stocks mentioned: BIIB, GRFS, HCA, UHS
Seeking Alpha - 9 months ago

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q4 2019 Results - Earnings Call Transcript

InvestorPlace - 1 year ago

These stocks slot into any portfolio and will pack a special punch.

Other stocks mentioned: AVP, CG, KGC, MANT, VIPS, WTR
InvestorPlace - 1 year ago

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

Other stocks mentioned: ACAD, ARWR, GLPG, NTRA, ONCE, ZLAB
Seeking Alpha - 1 year ago

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

As of September 18, 2019, the company received a non-binding proposal to be acquired for $120/share.

Seeking Alpha - 1 year ago

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2019 Results - Earnings Call Transcript

GuruFocus - 1 year ago

According to the GuruFocus All-In-One Screener, the following companies have grown their book value per share over the past decade.

Other stocks mentioned: BFR, DFS, MGA, UHAL
Seeking Alpha - 1 year ago

China Biologic Products Holdings, Inc. (CBPO) Management on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

China Biologic Products (CBPO) delivered earnings and revenue surprises of 12.12% and 8.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 1 year ago

China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNBC Television - 2 years ago

The fastest growing fast-casual franchise as restaurant spending surges

Jersey Mike's CEO Peter Cancro discusses his company's expansion as restaurant spending in the U.S. has surged in the last three months, to the most on record.

Other stocks mentioned: SBUX, STI

About CBPO

China Biologic Products Holdings engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provi... [Read more...]

Industry
Biotechnology
CEO
David Gao
Employees
2,246
Stock Exchange
NASDAQ
Ticker Symbol
CBPO
Full Company Profile

Financial Performance

In 2019, CBPO's revenue was $503.74 million, an increase of 7.90% compared to the previous year's $466.88 million. Earnings were $138.81 million, an increase of 8.40%.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CBPO stock is "Hold." The 12-month stock price forecast is 102.78, which is a decrease of -12.90% from the latest price.

Price Target
$102.78
(-12.90% downside)
Analyst Consensus: Hold